NCT05556421

Brief Summary

The investigators conducted a case-control study between December 2020-June 2021 at Istanbul Health Sciences University Kanuni Sultan Suleyman Training and Research Hospital family planning outpatient clinics. One hundred and forty-three patients who had copper intrauterine devices (T Cu 380 A) inserted for contraception were evaluated between the 6th week to 5 years after insertion. Patients were divided into two groups according to their ultrasonographic examinations as "displaced" or "normal" positions. Uterocervical angles were measured of both groups by transvaginal ultrasonography and investigated whether the uterocervical angle had any effect in predicting the displacement of copper intrauterine devices.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
123

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2021

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2021

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

September 22, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 27, 2022

Completed
Last Updated

September 12, 2025

Status Verified

September 1, 2022

Enrollment Period

5 months

First QC Date

September 22, 2022

Last Update Submit

September 7, 2025

Conditions

Keywords

displacementcontraceptionfamily planningT-Cu 380Auterocervical angle

Outcome Measures

Primary Outcomes (1)

  • uterocervical angle

    Uterocervical angle (UCA) is the angle measured in the triangle region between the anterior uterine segment and the cervical canal

    6 months

Secondary Outcomes (2)

  • uterine volume

    6 months

  • endometrial cavity length

    6 months

Study Arms (2)

case group

dislocated intrauterine device

Diagnostic Test: uterocervical angle

control group

normal intrauterine device position

Diagnostic Test: uterocervical angle

Interventions

uterocervical angleDIAGNOSTIC_TEST

uterocervical angles were measured for both groups by transvaginal ultrasonography and investigated whether the uterocervical angle had any effect in predicting the displacement of copper intrauterine devices.

case groupcontrol group

Eligibility Criteria

Age21 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

The female patients between the ages of 21-45 who applied to either gynecology or family planning outpatient clinics and who had been using copper IUD (T Cu 380-A) as a contraception method for the last 6 weeks to 5 years were included in the study. Patients were included in the study on a voluntary basis.

You may qualify if:

  • Patients aged between 21-45

You may not qualify if:

  • Patients under the age of twenty-one and over the age of 45
  • Patients applied to the hospital within the first 6 weeks after copper IUD insertion
  • Patients with Space-occupying lesions (polyp, fibroid) in the uterine cavity
  • Patients who have and/or had a pelvic inflammatory disease
  • Patients who had Ascus, Hgsil, Lgsil, CIN (1,2,3), carcinoma in situ, and malignancy in their smear results before the study started or detected during the study period, and patients who were done LEEP or conization procedures due to these pathologies.
  • Patients with Descensus uteri
  • Patients with cervical polyps
  • Patients with connective tissue disease I- Patients with uterine myomas or adenomyosis
  • Patients with uterine anomaly
  • Patients with vaginal infection or recurrent vaginitis and patients with abnormal uterine bleeding
  • l- Patients with immune-compromised situations such as AIDS, drug use, or cortisone treatment m- Patients using anticoagulants for any reason n- Patients who have known Copper allergy or rare Copper metabolism disease (Wilson disease)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kanuni Sultan Suleyman Training and Research Hospital

Istanbul, Istanbul, 34307, Turkey (Türkiye)

Location

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

September 22, 2022

First Posted

September 27, 2022

Study Start

January 1, 2021

Primary Completion

June 1, 2021

Study Completion

July 1, 2021

Last Updated

September 12, 2025

Record last verified: 2022-09

Data Sharing

IPD Sharing
Will not share

Locations